Skip to content

Validation of a Multimodal Algorithm for the Treatment of Fecal Incontinence

Validation of a Multimodal Algorithm for Treatment of Fecal Incontinence in Women: Study of the Efficacy of the Combination of Treatments on the Impact on Clinical Severity and Quality of Life, and on the Underlying Pathophysiology

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05026970
Enrollment
150
Registered
2021-08-30
Start date
2019-02-01
Completion date
2023-05-01
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fecal Incontinence

Keywords

fecal incontinence, anorectal physiology, pragmatic clinical trial

Brief summary

Thisi is a pragmatical clinical trial with the main aim of main aim of evaluating the effectiveness of the combination of treatments for the management of fecal incontinence (FI), on profiles of patients with IF based on pathophysiological criteria, measuring physiological, clinical and quality of life outputs. Secondary: 1. Evaluate the presence of SIBO, gluten-sensitive enteropathy, malabsorption of bile salts or sugars in patients with Bristol stools ≥5 that condition the fecal continuity. 2. Effect of change in fecal consistency on IF symptoms. 3. To evaluate the effect of the combination of treatments on anorectal physiology and neurophysiology (motor and sensory), clinical severity and quality of life. 4. Evaluate the persistence of the treatments to the three months of end of the same.

Detailed description

FI is a very prevalent condition in community dwelling women. We have previously studied the efectivenes of four treatments in women with FI as well as the effect on the anorectal physiology and neurophysiology. All treatments improved clinical symptoms of FI but there were no statistical differences between the treatments, that were Kegel exercises (K), biofeedback (BF)+K, electrostimulation (ES)+K, and transcutaneous neuromodulation (tNM)+K. With this prevoous study we have a clearer idea of the anorectal physiology which should allow to select patients for given treatments. For the present study we try to validate a multimodal algorithm to treat FI, taking into account the underlying pahtophysiology. It will have 2 differentiated stages: Stage 1: Patients with loose stools (Bristol \>5): they will be studied to determine the cause of the diahrrea (mainly food intolerances) and treated accordingly. If FI symptoms remain, patients will pass to: Stage 2: Patients with Bristol\<6 anf FI symptoms. They will be adressed to 3 combinations of treatments according to the pathophysiology that explain the symptoms, which will be: BF+ES+K: those patients with direct sphincter damage BF+tNM+K: patients with external anal sphincter dennervation and/or colonic motility disorders. BF alones: patients with FI mainly explained by a bad control of the pelvic floor function (akinesia/dyssynergia). All patients will be studied with High Resolution Anorectal Manometry, PNTML, endoanal unltrasonography. Clinical severity and QoL with dedicated intruments or questionnaires. If after 1sr stage, if so, patients have a clinical severity of Cleveland\<4 they will be followed up at 3 months with K, studued again their clinical severity and QoL. After 2nd stage, if so, 3-month of targeted treatment will be performed, and reevaluated with HRAM, PNTML and clinical questionnaires. They will be followed up at 3 monts with only K to study the persistance of the treatments.

Interventions

COMBINATION_PRODUCTBiofeedback+Electrostimulation+Kegel

Biofeedback (3 sessions) Electrostimulation (12 weeks daily treatment) Kegel exercises (twice daily)

DEVICEBiofeedback+Tibial Neuromodulation+Kegel

Biofeedback (3 sessions) Transcutaneous Neuromodulation (12 weeks daily treatment) Kegel exercises (twice daily)

COMBINATION_PRODUCTBiofeedback+Kegel

Biofeedback+Kegel exercises

Sponsors

Hospital de Mataró
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* FI episodes at least 6 months before * FI episodes each month * No other treatment the year before * Able to self-administer treatments

Exclusion criteria

* Pregnancy * If, to investigators criteria, patient will fail to administer the tratmetns properly, due to physical or psychic conditions

Design outcomes

Primary

MeasureTime frameDescription
Cleveland Severity Score3 month and 6 monthChanges in clinical severity after the treatments measured with Cleveland score, which ranges from 0 (total continence) to 20 (very severe incontinence)
Anorectal physiology (motor)3 month and 6 monthChanges in anal mean resting pressure and squeeze (voluntary) pressure after the treatments measured with mmHg
Anorectal physiology (sensorial)3 month and 6 monthChanges in rectal sensory thresholds after the treatments measured in volume (milliliters) of rectal distention
Anorectal neurophysiology3 month and 6 monthChanges in pudendal nerve terminal motor latency (PNTML) measured with milliseconds
Quality of Life (QoL) according to FIQL scale3 month and 6 monthImprovements in Fecal incontinence-related QoL after the treatments

Countries

Spain

Contacts

Primary ContactAlba Raventós, Nurse
albar.ravens92@gmail.com937417700
Backup ContactLluís Mundet
lluismundetp@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026